DGX Stock Up on New Blood Test Development Deal With MD Anderson

Key Takeaways Quest Diagnostics will co-develop a blood test with MD Anderson to detect elevated cancer risk. DGX will refine and validate MD Anderson's MCaST model for its lab-developed cancer risk test. DGX shares rose 2.6% after the news, adding to a 31.3% gain over the past year.Quest Diagnostics Inc. (DGX) recently announced a collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson). The partnership will focus on improving the assessment of elevated risk of cancer in individ ...